## EC Meeting held on 06<sup>th</sup> November 2024 at 02:00 PM in the DIRECTOR SIR ROOM, RIO, Ground Floor, Regional Institute of Ophthalmology, Kolkata-700073, West Bengal, India.

Following members were present in the meeting:

- 1. Dr. Santanu Sen
- 2. Dr. Purban Ganguly
- 3. Dr. Manab Nandi
- 4. # Dr. Lakshmi Kanta Mondal
- 5. Mr. Rajesh Arora
- 6. Mr. Rakesh Arora
- 7. Ms. Mandabi Bhattacharyya
- 8. Ms. Suparna Ray

Determination of quorum- Quorum was complete with the presence of eight members out of eight members.

Disclosure of Conflict of Interest: Chairman called for disclosure of Conflict of Interest (COI) in the protocols scheduled for deliberation in the meeting.

Reading and Approval of the minutes of the last meeting: The Chairperson presided over the discussion of the minutes of the meeting held on 06<sup>th</sup> November 2024. All members of the IEC approved the minutes.

1. IRB Committee: Establishment of an Institutional Scientific Review Committee/Board is essential to maintain the ethics for human safety, protection and proper rights ans also to evaluate the safety, efficacy and patient-benefits of the drug. Proper medical management is also a major concern of this scientific board

SL.	Agenda Item	Discussion	Action/Recommendatio n	Responsibility	Target Date	Remarks
1.	Dr. Asim Kumar Ghosh	A prospective, multi-center, open-label, phase IV study to evaluate the safety and effectiveness of intravitreal injections (IVI) of Brolucizumab in patients with Diabetic Macular Edema (DME).	Dr. Asim Kumar Ghosh presented this study in details in Power Point Slides before the members of Ethics Committee.	After detailed discussion, all the members present in the meeting unanimously APPROVED the decision to perform the EC work.		DECISION APPROVED

2.	Dr. Lakshmi Kanta Mondal	A multicenter, open label, randomized, active controlled, comparative, parallel group, phase 3 non-inferiority, clinical study to evaluate efficacy and safety of CPL0702 ophthalmic solution versus dorzolamide 2% ophthalmic solution and Brimonidine 0.1% ophthalmic solution given concurrently in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT).	Dr. Lakshmi Kanta Mondal presented this study in details in Power Point Slides before the members of Ethics Committee.	After detailed discussion, all the members present in the meeting unanimously APPROVED the decision to perform the EC work.	DECISION APPROVED
----	-----------------------------	---	--	---	-------------------

# He was absent during the discussion of the protocol to avoid Conflict of Interest, and the honorable Chairperson Dr. Santanu Sen participated as the Clinician together with played his role as Chairperson.

Jantany Sen 11/11/24

